January 25th, 2023

The French Ministry of Higher Education and Research has granted Enantia with the Crédit d’Impôt Recherche (CIR) (i.e., R&D tax credit) for a further three-year period: 2023, 2024 and 2025.

Thanks to the support of Crédit d’Impôt Recherche, French companies can incur research and development costs and be partially reimbursed for these expenses. The objective of this measure is to promote business innovation and competitiveness at national and international level.

We are glad to share this great news with our French customers, especially those with a strong R&D activity. This includes pharmaceutical companies, biotechs, CDMOs and CMOs, which can benefit from our CIR accreditation in all our services, such as medicinal chemistry, chemical development, solid state development and solid form analysis.

You can find our CIR accreditation here.

December 21th, 2022

May Christmas bring happiness and health to all of you and your loved ones.

We would like to express our deepest appreciation for the trust you have placed in us during this 2022.

Let’s continue to work together in the coming new year!

June 15th, 2022

Next June 17^th the ALBA Synchrotron will host the workshop: “ALBA Synchrotron Applications for the Pharmaceutical Industry” to show pharmaceutical companies the applications of synchrotron light. Studies at the synchrotron are a valuable ally for the pharmaceutical sector, for example, during the design of new drugs or the characterization of active ingredients in the final formulation.

The conference is aimed at managers and members of the R&D&i team from pharmaceutical and biomedical companies who wish to know more about how a synchrotron works and its main industrial applications.

Enantia is a frequent user of the ALBA synchrotron which has allowed us to build a solid experience exploiting its high sensitivity X-ray beam lines. We leverage our expertise to, for example, detect and quantify very small percentages of crystalline forms in complex matrixes including drug formulations, to determine the absolute configuration of an API and to confirm the formation of a cocrystal or a salt. Experiments performed by Enantia at the ALBA synchrotron are also used to support IP Hatch-Waxman Act litigation strategies both by plaintiff and defendant parties in Paragraph IV trials.

During the meeting, experienced staff from companies will present case studies involving the use of the ALBA synchrotron X-ray beam lines. Joan Farran, the head of Enantia’s Solid-State Analysis department, will be talking on behalf of Enantia about real examples of X-ray diffraction analysis that allowed advances in various stages of the development of pharmaceuticals products.

The event will also include a visit to the facilities as well as a networking lunch.

Attendance is free but registration is required through this website: https://indico.cells.es/e/workshopindustrialsalud

The event is organised in collaboration with BIOCAT and with the support of the European project LEAPS-Innov.

May 18th, 2022

We are pleased to share our consolidated expertise in drug discovery with young and passionate scientists by co-organising, along with the Spanish Society of Medicinal Chemistry (SEQT), the Seventh SEQT Summer School, which this year has been certified by the European Federation for Medicinal Chemistry and Chemical Biology (EFMC).

The event will take place next July 19-21^th 2022 in the Barcelona Science Park and it brings a great opportunity for approaching the pharma industry to young researchers working in the field of chemistry and life sciences. The participants will learn about the state of the art and new trends in drug discovery and development with experts from Almirall, Novartis, Merck, Janssen, FAES Farma, Gate2Brain and Enantia, amongst others.

To facilitate an optimal interaction with the speakers, the number of attendees is limited, therefore early registrations are strongly encouraged. The deadline for registrations is on the 15/06/22.

September 17th, 2021

Enantia has received one of the awards from the sixth edition of the Expoquimia Awards 2020 for Research, Development and Innovation in the field of chemistry.

This award recognizes the most innovative processes and the most sustainable products and chemical technologies. Enantia participated with its work in cannabinoids named “Co-crystals fish out cannabinoid from plant extract”, which highlights the potential of Enantia’s technology to develop efficient processes for the purification of cannabidiol (CBD) from natural sources and, in general, for the purification of high-value compounds from complex matrixes of either natural or synthetic origins. You can read more about this technology here.

We would like to thank the committee for this recognition, and congratulate the rest of the participants.

Picture: Dr. Sara Preciado (Head of IP and Innovation at Enantia) receiving the award at the Expoquimia 2021 event.

July 12th, 2021

It’s a pleasure to announce Enantia’s collaboration with the SEQT on their XX Awards, which will be given on the XX Congress of the SEQT. The meeting will be held in Santiago de Compostela from January 23th to 26th, 2022. Are you an early career researcher in the field of search and development of new drugs? Call is open until the 15th of July, look here for details and submit your work!

The Spanish Society of Medicinal Chemistry (SEQT) is a multidisciplinary, non-profit body created in 1977. It integrates all professionals, companies, and organizations whose activity is related to Spanish Pharmaceutical R+D. The goals of the SEQT are to promote the development of this field through the organization of scientific meetings that will stimulate professional contacts at both national and international levels, and to contribute to the training of advanced graduate students in the field. The SEQT is member of the European Federation for Medicinal Chemistry (EFMC), which groups the majority of graduates and professionals working in Pharmaceutical R+D.

July 7th, 2021

Our UNE-EN ISO 9001:2015 certificate has been renewed for our services in development and synthesis of organic compounds, as well as for the development, preparation and analysis of solid forms. This demonstrates, once again, Enantia’s high-quality standards to meet our customer’s requirements.

At Enantia we also undertake projects that require Good Manufacturing Practice (GMP) Certification that involve the synthesis of drug candidates and active pharmaceutical ingredients, as well as the preparation of solid forms like cocrystals, salts, polymorphs and solvates of a given compound, delivered by our trusted GMP-certified partners.